Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE DATED MARCH 2, 2017 - H-CYTE, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date of
Report (Date of earliest event reported) March 6, 2017
MEDOVEX CORP.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
333-198621
|
46-3312262
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
3279 Hardee Avenue
Atlanta, Georgia 30341
(Address
of principal executive offices, including zip code)
(844) 633-6839
(Registrant's
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 3.01 Notice of Delisting or Failure to
Satisfy a Continued Listing Rule or Standard: Transfer of
Listing
On
March1, 2017, Nasdaq issued a determination that the Company has
evidenced compliance with the minimum stockholders’ equity
requirement for continued listing on the Nasdaq Capital
Market.
Item
7.01 Regulation FD Disclosure
On
March 2, 2017, Medovex Corp. (the “Company”) issued a
press release upon receiving Nasdaq’s determinations that the
Company has evidenced compliance with NASDAQ’s
stockholders’ equity requirement for continued listing. . A
copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
The
information contained in this Current Report on Form 8-K shall not
be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or incorporated by reference in any filing under the
Securities Act of 1933, as amended (the “Securities
Act”) or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing. The furnishing of the
information in this Current Report on Form 8-K is not intended to,
and does not, constitute a representation that such furnishing is
required by Regulation FD or that the information contained in this
Current Report on Form 8-K constitutes material investor
information that is not otherwise publicly available.
The
Securities and Exchange Commission encourages registrants to
disclose forward-looking information so that investors can better
understand the future prospects of a registrant and make informed
investment decisions. This Current Report on Form 8-K and exhibits
may contain these types of statements, which are
“forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, and which involve
risks, uncertainties and reflect the Registrant’s judgment as
of the date of this Current Report on Form 8-K. Forward-looking
statements may relate to, among other things, operating results and
are indicated by words or phrases such as “expects,”
“should,” “will,” and similar words or
phrases. These statements are subject to inherent uncertainties and
risks that could cause actual results to differ materially from
those anticipated at the date of this Current Report on Form 8-K.
The Company disclaims any obligation to, and will not, update any
forward-looking statements to reflect events or circumstances after
the date hereof. Investors are cautioned not to rely unduly on
forward-looking statements when evaluating the information
presented within.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press
Release dated March 2, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
MEDOVEX CORP
|
|
|
Dated:
March 6, 2017
|
|
|
|
|
By:
|
/s/ Jarrett
Gorlin
|
|
|
Name:
Title:
|
Jarrett
Gorlin
Chief
Executive Officer
|
|
|
|
|